Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 1 hour 9 min ago

Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer

Wed, 09/09/2015 - 15:28
LEXINGTON, Mass.--(Healthcare Sales & Marketing Network)--Synta Pharmaceuticals Corp. (SNTA) today announced the appointment of Alan C. Rigby, Ph.D., as the Company’s Senior Vice President and Chief Scientific Officer. Dr. Rigby brings over 20 years of aca...
Biopharmaceuticals, Oncology, Personnel
Synta Pharmaceuticals, ganetespib

Vanda Pharmaceuticals Announces the Appointment of European General Manager

Tue, 09/08/2015 - 20:17
WASHINGTON, Sept. 8, 2015 -- (Healthcare Sales & Marketing Network) -- Vanda Pharmaceuticals Inc. (Vanda) (VNDA) today announced that it has named Gian Piero Reverberi as Vanda's Senior Vice President, European General Manager. Mr. Reverberi has more than...
Biopharmaceuticals, Personnel
Vanda Pharmaceuticals

Selecta Announces $38 Million Series E Financing

Tue, 09/08/2015 - 19:26
Proceeds from financing to enable advancement of multiple product pipeline of antigen-specific immunotherapies and vaccines Phase 2 study of lead immunotherapeutic candidate, SEL-212, in gout planned to start in 2016 WATERTOWN, Mass.--(Healthcare Sal...
Biopharmaceuticals, Venture Capital
Selecta Biosciences, Synthetic Vaccine Particle

Selecta Biosciences Appoints Earl E. Sands, MD, as Chief Medical Officer

Tue, 09/08/2015 - 14:25
WATERTOWN, Mass.--(Healthcare Sales & Marketing Network)--Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies using Synthetic Vaccine Particles (SVP), today announced the ...
Biopharmaceuticals, Personnel
Selecta Biosciences, immune modulating nanomedicine

Lombard Medical Names David Milne to Board of Directors

Tue, 09/08/2015 - 14:24
IRVINE, Calif., Sept. 8, 2015 -- (Healthcare Sales & Marketing Network) -- Lombard Medical Inc. (EVAR), a medical device company focused on endovascular aortic repair of abdominal aortic aneurysms, today announced that medical device executive and investor...
Devices, Interventional, Personnel
Lombard Medical, Aorfix, abdominal aortic aneurysm, AAA

Thoratec Announces Start Of Shield II(TM) U.S. Clinical Trial

Fri, 09/04/2015 - 15:09
PLEASANTON, Calif., Sept. 4, 2015 -- (Healthcare Sales & Marketing Network) -- Thoratec Corporation (THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced today that it has begun enrollmen...
Devices, Interventional Cardiology
Thoratec, SHIELD II, HeartMate PHP

U.S. FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine ACE910 for People With Hemophilia A With Factor VIII Inhibitors

Fri, 09/04/2015 - 15:02
First factor VIIIa-mimetic bispecific antibody to be investigated for the prophylactic treatment of hemophilia A Ninth breakthrough therapy designation for Genentech’s portfolio of medicines SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing ...
Biopharmaceuticals, FDA
Genentech, Roche Group, Hemophilia, ACE910

Helsinn Group Signs Exclusive Agreement With Mundipharma for the Distribution and Licence of anamorelin in Switzerland and Liechtenstein

Thu, 09/03/2015 - 13:11
This exclusive agreement builds on broad partnerships with Mundipharma in cancer supportive care across multiple global territories LUGANO and BASEL, Switzerland, September 3, 2015 -- (Healthcare Sales & Marketing Network) -- Helsinn, the Swiss Group f...
Biopharmaceuticals, Licensing, Distribution
Helsinn Group, Mundipharma, anamorelin

Atopix Therapeutics Appoints Dr Andrew Zambanini as Chief Medical Officer

Thu, 09/03/2015 - 12:59
ABINGDON, England, September 3, 2015 -- (Healthcare Sales & Marketing Network) -- Atopix Therapeutics Limited ("Atopix"), a UK biotechnology company developing a novel class of medicines to treat atopic dermatitis and severe asthma, today announ...
Biopharmaceuticals, Personnel
Atopix Therapeutics, CRTH2 antagonist

Atossa Genetics, Inc. Announces Appointment of Scott Youmans as Chief Operating Officer

Wed, 09/02/2015 - 19:28
SEATTLE, WA--(Healthcare Sales & Marketing Network) - Atossa Genetics, Inc. (NASDAQ: ATOS), a healthcare company focused on improving breast health through the development of pharmaceuticals to treat breast health conditions and through commercialization o...
Devices, Diagnostics, Personnel
Atossa Genetics

Exosome Diagnostics Raises $17.6 Million in Second Round Series B Financing

Wed, 09/02/2015 - 19:22
Funds will support commercial launch of multiple liquid biopsy cancer tests in 2015 and development of neurodegenerative exosome-based diagnostics CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Exosome Diagnostics, Inc., a developer of revolu...
Diagnostics, Venture Capital
Exosome Diagnostics, biofluid, exosome

Ascletis Secures US$35 Million Financing

Wed, 09/02/2015 - 19:14
SHANGHAI, Sept. 2, 2015 -- (Healthcare Sales & Marketing Network) -- Ascletis announced today the completion of a US$35 million (RMB 220 million) financing. The investment was led by C-Bridge Capital, joined by Tasly Pharmaceutical and Singapore-based Pav...
Biopharmaceuticals, Venture Capital
Ascletis Pharmaceuticals

Summit Therapeutics Appoints Ralf Rosskamp, MD, as Chief Medical Officer

Wed, 09/02/2015 - 14:34
OXFORD, United Kingdom, Sept. 2, 2015 -- (Healthcare Sales & Marketing Network) -- Summit Therapeutics plc (SUMM.L) (SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and C. difficile infection ('...
Biopharmaceuticals, Personnel
Summit Therapeutics

ADC Therapeutics Secures $80m Financing to Progress Its Pipeline of Antibody Drug Conjugate Therapeutics in Oncology

Wed, 09/02/2015 - 14:27
LAUSANNE, Switzerland & LONDON & MURRAY HILL, N.J.--(Healthcare Sales & Marketing Network)--ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targe...
Biopharmaceuticals, Oncology, Venture Capital
ADC Therapeutics, Antibody Drug Conjugates

Titan Spine Enters Distribution Agreement with MBA to Expand Endoskeleton(R) Titanium Implant Portfolio Offering in Europe

Wed, 09/02/2015 - 13:54
To Further Penetrate Markets of Six EU Countries, Broaden Surgeon Adoption Company opens new office in Spain to directly support relationship with Spanish and Portuguese markets MEQUON, Wis.--(Healthcare Sales & Marketing Network)--Titan Spine, a med...
Devices, Orthopaedic, Neurosurgery, Distribution
Titan Spine, Endoskeleton, interbody, spine surgery

SI-BONE, Inc. Appoints Karen Licitra and Keith Valentine to its Board of Directors

Tue, 09/01/2015 - 15:38
SAN JOSE, Calif., Sept. 1, 2015 -- (Healthcare Sales & Marketing Network) -- SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System®, a minimally invasive surgical (MIS) device indicated for fusion for certain disor...
Devices, Orthopaedic, Neurosurgery, Personnel
SI-BONE, iFuse Implant System, sacroiliac

CeQur Announces $100 Million Series C Financing

Tue, 09/01/2015 - 15:35
Funds will facilitate ongoing clinical and regulatory activities as well as commercial scale up for the world's first three-day simple insulin infusion device for type 2 diabetes World-class management team expedites fully optimized second-generation de...
Devices, Drug Delivery, Endocrinology, Venture Capital
CeQur, insulin delivery device

Matinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer

Tue, 09/01/2015 - 15:26
Co-Inventor of the Company's Proprietary Lipid-Crystal Nano-Particle Cochleate Technology Joins Management Sept. 1 BEDMINSTER, N.J., Sept. 1, 2015 -- (Healthcare Sales & Marketing Network) -- Matinas BioPharma Holdings, Inc. (MTNB), a clinical-stage bio...
Biopharmaceuticals, Drug Delivery, Personnel
Matinas BioPharma, nano-particle, amphotericin B

Intellia Therapeutics Secures $70 Million in Series B Financing

Tue, 09/01/2015 - 15:22
Funds to Accelerate Discovery and Development of Curative Products Based on CRISPR/Cas9 Gene-Editing Technology Pipeline Primarily Focused on Disorders of the Liver and Blood CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Intellia Therapeu...
Biopharmaceuticals, Venture Capital, Personnel
Intellia Therapeutics

Surefire Medical Receives FDA Clearance for Precision Direct-to-Tumor Embolization Device

Tue, 09/01/2015 - 15:14
WESTMINSTER, Colo.--(Healthcare Sales & Marketing Network)--Surefire Medical, Inc., developer of a new class of direct-to-tumor treatment delivery devices employed in minimally invasive chemoembolization and radioembolization procedures, announced that the...
Devices, Drug Delivery, Interventional, Oncology, FDA
Surefire Medical, Surefire Precision, chemoembolization, radioembolization

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong